• BioLineRx Announces Submission of Phase 3 Registrational Study for BL-8040 pharmaceutical-technology
    August 23, 2017
    BioLineRx announced the filing of regulatory submissions required to commence a randomized, controlled Phase 3 registrational trial of BL-8040 for the mobilization of hematopoietic stem cells for autologous transplantation in patients with multiple myelom
PharmaSources Customer Service